A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


August 6, 2012

What Do U.S. Women at Risk for HIV Think About PrEP?

by Trenton Straube

AIDS 2012Most U.S. women at risk for HIV are unaware of PrEP—pre-exposure prophylaxis, which entails taking daily meds to prevent HIV—but they view it as an option that should be available to all sexually active women. What’s more, their chief rationale “had something to do with not trusting what men were up to.” Such were the findings of a qualitative, focus-group study of at-risk women presented by Judith Auerbach, PhD, research consultant to AIDS United and the San Francisco AIDS Foundation, during the XIX International AIDS Conference in Washington, DC.

In 2009, women accounted for nearly 23 percent of new HIV infections in the United States, with black and Latino women being particularly at risk. As Auerbach said: “Clearly, more effective prevention strategies for women are needed.” One potential strategy is taking Truvada (tenofovir plus emtrictabine) as PrEP, which the Food and Drug Administration approved this summer. However, no clinical trials have focused on U.S. women; instead, trials have been primarily based in Africa, where results were mixed, likely because of low adherence to the regimen.

To gauge the knowledge and attitudes about PrEP among U.S. women, Auerbach and her colleagues organized focus group studies with a total of 92 women who perceived themselves to be HIV negative. Participants were considered to be at risk for the virus because of their social networks, sex and drug practices or socioeconomic status. Fifty-five percent were between 31 and 50 years old; 69 percent were black; 19 percent were Latino; 50 percent were employed; and 59 percent had at least some college. In addition, 27 percent perceived themselves at risk of getting HIV in the next year.

Focus groups were held in Washington, DC; Memphis, Tennessee; and Oakland and San Diego, California. Facilitators from local community groups recruited and led the focus groups, which began with background information about HIV and PrEP. Discussion topics included “For which women might PrEP be most helpful,” “Best sources of information about PrEP,” and “Potential impact of PrEP on women’s sex life, including use of condoms” among other subjects. Researchers then analyzed at the transcripts for underlying themes and to see if there were differences among the sites.

A range of opinions surfaced. “What’s really interesting,” Auerbach notes, “is the interaction that occurred during the course of the discussion. You can see a real divergence of opinion, and sometimes people would change their mind in the course of interaction with other women.”

One aspect was clear: Only about five out the 92 had heard of PrEP before the focus group. However, Auerbach said, “A number of women in all the groups mentioned that PrEP ought to be available for every woman, and chiefly the rational…had something to do with not trusting what men were up to.” They believed it was a helpful option for a range of women—sex workers, women whose partners have been in prison, women who experience sexual violence, black and Latino women—and for a variety of reasons. One woman suggested giving it to teens, noting the pregnancy rate as proof that unprotected sex was going on among youth. Another participant worried that giving young women PrEP would encourage them to be promiscuous.

Concerns about PrEP included efficacy, availability, adherence, side effects and the cost. “We have to be realistic about…the socio economics of our community, the underserved,” one participant said: “It has to be free.”

A common theme the researchers encountered was the mistrust of men (“you don’t know if your partner is faithful to you”), along with mistrust of the government and the medical system (participants mentioned the legacy of the “Tuskegee situation” as well as conflicting data about hormone replacement therapy). This mistrust was more profound among the African-American women. In addition, some participants noted that the church, specifically in the South and in rural America, would hinder PrEP as well as frank discussions about sex and HIV.

Participants suggested that trusted medical providers, community organizations and Planned Parenthood would be good venues through which to get PrEP to women, but it was noted that if PrEP is marketed only to black women, it might be viewed as a conspiracy.

Members of the focus groups were asked whether they thought women and men on PrEP would continue to use condoms. Opinions varied, Auerbach said, but the women were aware of other sexually transmitted infections and they mentioned that as a reason to continue condom use. Others felt it was likely that both men and women on PrEP would skip the condoms.

What was clear throughout the discussions, Auerbach said, was that women desired to have some way that they control their sexual health, especially since they didn’t trust their male partners. “A majority [of participants] at some moment concluded that [PrEP] was a reasonable option.”

Search: hiv, prep, pre-exposure prophylaxis, transmission, prevention, women, attitudes, men, aids 2012, auerbach

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.